and human data to transfo Eli Lilly and Company (NYSE: LLY) announced today that it has elected Jon Moeller as a new member of its board of directors, effective Dec. 1, 2024. In addition ...

Appointment of José Antonio Alas brings more than 30 years of biotech expertise, including global business development, ...

Seven Bridges Specialty, a specialty pharmacy services innovator, is proud to announce the appointment of Steve Granzyk as President and Chief Executive Officer. Steve brings over three decades of ...

Many of Indiana’s largest law firms find it imperative to offer government lobbying for their clients in order to provide a ...

The Harrison County Community Foundation recently announced Samantha Carr as the recipient of the 2025 Lilly Endowment ...

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

Sales of Eli Lilly's lead drug, tirzepatide, which it markets as Zepbound for weight loss and Mounjaro for diabetes, leapt up to a combined $5.4 billion in the fourth quarter. That's some amazing ...

Eli Lilly (NYSE: LLY) began a roll in late 2020 that lasted almost four years. During that time, it became the world's ...

In the first half of 2024, it seemed Eli Lilly (NYSE: LLY) could do no wrong. Unfortunately, the good times didn't last very long. The stock peaked last October and was down by more than 21% when ...

2024 was an interesting year for pharmaceutical powerhouse Eli Lilly (NYSE: LLY). At one point, share prices had gained as much as 65% on the year. However, after a less-than-spectacular earnings ...

We recently compiled a list of the 10 Best Stocks to Invest in According to Billionaire Cliff Asness. In this article, we are ...